

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the specification.

Listing of Claims:

Claim 1 (currently amended): A pharmaceutical composition ~~combination~~ comprising ~~as active ingredients~~;

- (i) a renin inhibitor or a pharmaceutically acceptable salt thereof; and
- (ii) a least one PDGF receptor tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof.

Claim 2 (currently amended): The composition ~~combination according to~~ of claim 1 wherein the PDGF receptor tyrosine kinase inhibitors are selected from 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide methanesulfonate, 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, CT52923, (4-(6,7-dimethoxy-4-quinazolinyl)-N-(3,4-methylenedioxybenzyl)-1-piperazinethiocarboxamide), RP-1776, GFB-111, pyrrolo[3,4-c]-beta-carboline-diones, SU 102, AG1296, AG1296 and RPR101511A or, in each case, a pharmaceutically acceptable salt thereof.

Claim 3 (currently amended): The ~~combination according to~~ composition of claim 1 ~~or claim 2~~ wherein the renin inhibitor is selected from 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide, detikiren, terlakiren and zankiren, or a pharmaceutically acceptable salt thereof.

Claim 4 (currently amended): The ~~combination according to~~ composition of claim 1 ~~or claim 2~~ wherein the renin inhibitor is 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide, or a pharmaceutically acceptable salt thereof.

Claim 5 (currently amended): A ~~combination~~ pharmaceutical composition comprising ~~as active ingredients~~;

- (i) 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide or a pharmaceutically acceptable salt thereof; and

(ii) a PDGF receptor tyrosine kinase inhibitor selected from N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, or in each case a pharmaceutically acceptable salt thereof.

Claim 6 (currently amended): ~~The combination according to~~ composition of claim 4 ~~or claim 5~~ wherein the active ingredient (i) is in the form of its hemi-fumarate salt, and the active ingredient (ii) is in the form of a its monomesylate salt.

Claim 7 (cancel):

Claim 8 (currently amended): ~~The present invention also relates to a~~ A method for the prevention, delay of progression or treatment of a disease and disorder selected from cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis, restenosis, cardiovascular hypertrophy or cardiovascular hypertrophic remodeling or hypertension-induced cardiovascular diseases, cardiac hypertrophy, cardiac remodeling after myocardial infarction, pulmonary congestion and cardiac fibrosis in dilated or in hypertrophic cardiomyopathy, left or right ventricular hypertrophy, diabetic myopathy, stroke prevention in congestive heart failure, hypertrophic medial thickening in arteries and/or in large vessels, hypertension-induced vascular injuries, mesenteric vasculature hypertrophy, renal hyperfiltration such as after portal renal ablation, proteinuria in chronic renal disease, renal arteriopathy as a consequence of hypertension, ~~Nephrosclerosis~~ nephrosclerosis or hypertensive nephrosclerosis, mesangial hypertrophy, hypertension, congestive heart failure, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis, macular degeneration, cataracts, premenstrual syndrome, skin and connective tissue disorders, endothelial dysfunction and impaired vascular compliance, comprising administering to a warm-blooded animal~~[[,]] including man[[,]]~~ in need thereof ~~jointly a therapeutically effective amounts~~ amount of a ~~combination according to any one of claims 1 to 7~~ pharmaceutical composition of claim 1.

Claim 9 (cancel):

Claim 10 (original): A kit of parts comprising

- (i) an amount of a renin inhibitor in a first unit dosage form;
- (i) an amount of at least one PDGF receptor tyrosine kinase inhibitor, or,

in each case, where appropriate, a pharmaceutically acceptable salt thereof, in the form of two or three or more separate units of the components (i) to (ii).

Claim 11 (currently amended): ~~The use according to claim 9,~~ A method of using a kit of parts according to claim 10, wherein the renin inhibitor is selected from the group consisting of aliskiren, detikiren, terlakiren, and zankiren.

Claim 12 (currently amended): ~~The use according to claim 9 or 11,~~ A method of using the kit of parts according to claim 10 ~~or 11~~, wherein the PDGF receptor tyrosine kinase inhibitors are selected from 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide methanesulfonate, 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, CT52923, (4-(6,7-dimethoxy-4-quinazolinyl)-N-(3,4-methylenedioxybenzyl)-1-piperazinethiocarboxamide), RP-1776, GFB-111, pyrrolo[3,4-c]-beta-carboline-diones, SU 102, AG1296, AG1296 and RPR101511A or, in each case, a pharmaceutically acceptable salt thereof.

Claim 13 (cancel):

Claim 14 (cancel):

Claim 15 (new): The pharmaceutical composition according to claim 2 wherein the renin inhibitor is selected from 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide, detikiren, terlakiren and zankiren, or a pharmaceutically acceptable salt thereof.

Claim 16 (new): The pharmaceutical composition of claim 5 wherein the active ingredient (i) is in the form of its hemi-fumarate salt, and the active ingredient (ii) is in the form of a its monomesylate salt.

Claim 17 (new): A method for the prevention, delay of progression or treatment of a disease and disorder selected from cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis, restenosis, cardiovascular hypertrophy or cardiovascular hypertrophic remodeling or hypertension-induced cardiovascular diseases, cardiac hypertrophy, cardiac remodeling after myocardial infarction, pulmonary congestion and cardiac fibrosis in dilated or in hypertrophic cardiomyopathy, left or right ventricular hypertrophy, diabetic myopathy, stroke prevention in congestive heart failure, hypertrophic medial thickening in arteries and/or in large vessels, hypertension-induced vascular injuries, mesenteric vasculature hypertrophy, renal hyperfiltration

such as after portal renal ablation, proteinuria in chronic renal disease, renal arteriopathy as a consequence of hypertension, nephrosclerosis or hypertensive nephrosclerosis, mesangial hypertrophy, hypertension, congestive heart failure, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis, macular degeneration, cataracts, premenstrual syndrome, skin and connective tissue disorders, endothelial dysfunction and impaired vascular compliance, comprising administering to a warm-blooded animal in need thereof therapeutically effective amount of a pharmaceutical compositor according to claim 2.

Claim 18 (new): A method for the prevention, delay of progression or treatment of a disease and disorder selected from cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis, restenosis, cardiovascular hypertrophy or cardiovascular hypertrophic remodeling or hypertension-induced cardiovascular diseases, cardiac hypertrophy, cardiac remodeling after myocardial infarction, pulmonary congestion and cardiac fibrosis in dilated or in hypertrophic cardiomyopathy, left or right ventricular hypertrophy, diabetic myopathy, stroke prevention in congestive heart failure, hypertrophic medial thickening in arteries and/or in large vessels, hypertension-induced vascular injuries, mesenteric vasculature hypertrophy, renal hyperfiltration such as after portal renal ablation, proteinuria in chronic renal disease, renal arteriopathy as a consequence of hypertension, nephrosclerosis or hypertensive nephrosclerosis, mesangial hypertrophy, hypertension, congestive heart failure, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis, macular degeneration, cataracts, premenstrual syndrome, skin and connective tissue disorders, endothelial dysfunction and impaired vascular compliance, comprising administering to a warm-blooded animal in need thereof therapeutically effective amount of a pharmaceutical compositor according to claim 3.

Claim 19 (new): A method for the prevention, delay of progression or treatment of a disease and disorder selected from cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis, restenosis, cardiovascular hypertrophy or cardiovascular hypertrophic remodeling or hypertension-induced cardiovascular diseases, cardiac hypertrophy, cardiac remodeling after myocardial infarction, pulmonary congestion and cardiac fibrosis in dilated or in hypertrophic cardiomyopathy, left or right ventricular hypertrophy, diabetic myopathy, stroke prevention in congestive heart failure, hypertrophic medial thickening in arteries and/or in large vessels, hypertension-induced vascular injuries, mesenteric vasculature hypertrophy, renal hyperfiltration

such as after portal renal ablation, proteinuria in chronic renal disease, renal arteriopathy as a consequence of hypertension, nephrosclerosis or hypertensive nephrosclerosis, mesangial hypertrophy, hypertension, congestive heart failure, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis, macular degeneration, cataracts, premenstrual syndrome, skin and connective tissue disorders, endothelial dysfunction and impaired vascular compliance, comprising administering to a warm-blooded animal in need thereof therapeutically effective amount of a pharmaceutical compositor according to claim 4.

Claim 20 (new): A method for the prevention, delay of progression or treatment of a disease and disorder selected from cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis, restenosis, cardiovascular hypertrophy or cardiovascular hypertrophic remodeling or hypertension-induced cardiovascular diseases, cardiac hypertrophy, cardiac remodeling after myocardial infarction, pulmonary congestion and cardiac fibrosis in dilated or in hypertrophic cardiomyopathy, left or right ventricular hypertrophy, diabetic myopathy, stroke prevention in congestive heart failure, hypertrophic medial thickening in arteries and/or in large vessels, hypertension-induced vascular injuries, mesenteric vasculature hypertrophy, renal hyperfiltration such as after portal renal ablation, proteinuria in chronic renal disease, renal arteriopathy as a consequence of hypertension, nephrosclerosis or hypertensive nephrosclerosis, mesangial hypertrophy, hypertension, congestive heart failure, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis, macular degeneration, cataracts, premenstrual syndrome, skin and connective tissue disorders, endothelial dysfunction and impaired vascular compliance, comprising administering to a warm-blooded animal in need thereof therapeutically effective amount of a pharmaceutical compositor according to claim 5.

Claim 21 (new): A method for the prevention, delay of progression or treatment of a disease and disorder selected from cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis, restenosis, cardiovascular hypertrophy or cardiovascular hypertrophic remodeling or hypertension-induced cardiovascular diseases, cardiac hypertrophy, cardiac remodeling after myocardial infarction, pulmonary congestion and cardiac fibrosis in dilated or in hypertrophic cardiomyopathy, left or right ventricular hypertrophy, diabetic myopathy, stroke prevention in congestive heart failure, hypertrophic medial thickening in arteries and/or in large vessels, hypertension-induced vascular injuries, mesenteric vasculature hypertrophy, renal hyperfiltration

such as after portal renal ablation, proteinuria in chronic renal disease, renal arteriopathy as a consequence of hypertension, nephrosclerosis or hypertensive nephrosclerosis, mesangial hypertrophy, hypertension, congestive heart failure, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis, macular degeneration, cataracts, premenstrual syndrome, skin and connective tissue disorders, endothelial dysfunction and impaired vascular compliance, comprising administering to a warm-blooded animal in need thereof therapeutically effective amount of a pharmaceutical compositor according to claim 6.